Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
PTGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.31 - $61.89
Previous CloseN/A
Volume120.35K
Average Volume (3M)730.99K
Market Cap
$3.77B
Enterprise Value$2.95B
Total Cash (Recent Filing)$570.47M
Total Debt (Recent Filing)$11.28M
Price to Earnings (P/E)78.9
Beta0.84
Next Earnings
Nov 05, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding62,211,320
10 Day Avg. Volume981,441
30 Day Avg. Volume730,992
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue14.49
Enterprise Value/Gross Profit14.54
Enterprise Value/Ebitda116.19
Forecast
1Y Price Target
$72.00Price Target Upside23.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe NDA for icotrokinra in patients with severe plaque psoriasis is supported by 4 pivotal Phase 3 studies, indicating strong data backing its approval.
Market PotentialIcotrokinra is expected to achieve blockbuster status in psoriasis and capture significant market share in ulcerative colitis and psoriatic arthritis.
Strategic DevelopmentThe company's ability to develop assets like PN-881 and PN-477 to a significant point highlights financial stability and strategic foresight.
Bears Say
CompetitionPreclinical data suggest PN-477 may result in more weight loss than retatrutide, a similar triple receptor agonist that has shown the best efficacy in obesity so far.
Financial TermsPTGX is entitled to $35M upon the NDA filing for icotrokinra and $50M upon FDA approval, after which the tiered royalties that PTGX will receive on net product sales will range from 6% to 10%.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $33.31 and its highest was $61.89 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $3.77B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 55 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.579 by $0.029.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.61.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 62,211,320 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.579. Following the earnings report the stock price went down -5.384%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.00 (23.37% Upside)
$72.00 (23.37% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 607.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.39%
12-Months-Change
Fundamentals
Return on Equity
8.61%
Trailing 12-Months
Asset Growth
16.82%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX Stock 12 Month Forecast
Average Price Target
$72.00
▲(23.37% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Merus
―
Crispr Therapeutics AG
―
Scholar Rock Holding
―
Ownership Overview
1.64% Insiders
15.14% Mutual Funds
54.64% Other Institutional Investors
6.04% Public Companies and
Individual Investors